FHTX
Foghorn Therapeutics Inc. NASDAQ Listed Oct 23, 2020$4.20
Pre-mkt
$4.31
+1.65%
Mkt Cap $246.5M
52w Low $3.27
25.3% of range
52w High $6.95
50d MA $5.08
200d MA $5.06
P/E (TTM)
-4.0x
EV/EBITDA
-3.8x
P/B
—
Debt/Equity
-0.4x
ROE
68.5%
P/FCF
-3.9x
RSI (14)
—
ATR (14)
—
Beta
3.11
50d MA
$5.08
200d MA
$5.06
Avg Volume
152.6K
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
500 Technology Square · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | -0.28 | -0.34 | -21.4% | 5.65 | -0.9% | -12.9% | -0.4% | +1.4% | +1.8% | -3.6% | — |
| Nov 5, 2025 | AMC | -0.31 | -0.25 | +19.4% | 4.00 | +0.2% | +0.0% | +9.0% | +1.4% | +0.5% | +2.0% | — |
| Aug 5, 2025 | AMC | -0.31 | -0.28 | +9.7% | 5.00 | +0.2% | -2.0% | +1.6% | -8.0% | +2.8% | +3.4% | — |
| May 14, 2025 | AMC | -0.30 | -0.30 | +0.0% | 4.11 | -0.2% | +4.9% | +2.8% | -5.0% | -1.7% | -1.9% | — |
| Mar 6, 2025 | AMC | -0.43 | -0.30 | +30.2% | 4.50 | -1.1% | +0.4% | -2.7% | +0.9% | +3.2% | -2.2% | — |
| Nov 4, 2024 | AMC | -0.42 | -0.31 | +26.2% | 8.24 | -2.7% | +8.5% | +3.4% | -1.4% | +2.6% | -0.7% | — |
| Aug 8, 2024 | AMC | -0.60 | -0.45 | +25.0% | 5.24 | -1.0% | +0.2% | +6.1% | +6.1% | -5.2% | +10.7% | — |
| May 6, 2024 | AMC | -0.55 | -0.59 | -7.3% | 5.83 | +0.0% | -3.4% | +6.2% | -0.7% | -6.4% | +2.0% | — |
| Mar 7, 2024 | AMC | -0.79 | -0.57 | +27.8% | 6.83 | +2.3% | -3.5% | +3.3% | -4.0% | +3.4% | -10.5% | — |
| Nov 2, 2023 | AMC | -0.72 | -0.34 | +52.8% | 3.94 | -0.3% | -2.8% | -9.3% | +0.6% | -0.4% | -2.9% | — |
| Aug 4, 2023 | AMC | -0.73 | -0.70 | +4.1% | 9.21 | -0.1% | +0.3% | +0.1% | +2.1% | +0.7% | +2.1% | — |
| May 8, 2023 | AMC | -0.68 | -0.73 | -7.4% | 5.43 | -2.9% | -1.1% | +14.7% | -0.5% | +3.4% | +1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $5.65 | $5.60 | -0.9% | -12.9% | -0.4% | +1.4% | +1.8% | -3.6% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.48 | $5.45 | -0.5% | +0.2% | +2.9% | -12.9% | -0.4% | +1.4% |
| Feb 17 | Jefferies | Maintains | Buy → Buy | — | $5.55 | $5.49 | -1.1% | +0.2% | +1.8% | +3.0% | -1.7% | +0.3% |
| May 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.11 | $4.10 | -0.2% | +4.9% | +2.8% | -5.0% | -1.7% | -1.9% |
| Apr 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.25 | $4.13 | -2.8% | -1.2% | -1.0% | +1.9% | -8.5% | +2.6% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.25 | $4.13 | -2.8% | -1.2% | -1.0% | +1.9% | -8.5% | +2.6% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.45 | -1.1% | +0.4% | -2.7% | +0.9% | +3.2% | -2.2% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.51 | $5.34 | -3.1% | +0.0% | -10.9% | +1.4% | +3.2% | -4.1% |
| Dec 16 | Jefferies | Maintains | Buy → Buy | — | $5.30 | $4.67 | -11.9% | +4.0% | +0.0% | -10.9% | +1.4% | +3.2% |
| Sep 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.32 | $9.41 | +1.0% | +2.6% | -4.3% | +5.8% | -3.3% | -0.5% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.25 | $5.31 | +1.1% | +6.1% | +6.1% | -5.2% | +10.7% | +1.0% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $5.24 | $5.19 | -1.0% | +0.2% | +6.1% | +6.1% | -5.2% | +10.7% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.83 | $5.83 | +0.0% | -3.4% | +6.2% | -0.7% | -6.4% | +2.0% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.46 | $5.48 | +0.4% | +7.3% | +4.3% | -2.0% | -2.7% | -3.4% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.48 | $7.18 | -4.0% | -2.9% | +10.2% | -7.2% | -13.9% | -5.6% |
| Apr 10 | Wedbush | Maintains | Outperform → Outperform | — | $7.48 | $7.18 | -4.0% | -2.9% | +10.2% | -7.2% | -13.9% | -5.6% |
| Mar 8 | Wedbush | Maintains | Outperform → Outperform | — | $6.83 | $6.99 | +2.3% | -3.5% | +3.3% | -4.0% | +3.4% | -10.5% |
| Nov 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.23 | $3.19 | -1.2% | +12.1% | +9.4% | +1.3% | -5.7% | +12.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.21 | $9.20 | -0.1% | +0.3% | +0.1% | +2.1% | +0.7% | +2.1% |
| Jul 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.85 | $6.85 | +0.0% | -0.4% | +12.8% | -4.8% | +1.0% | +4.7% |
| Jun 29 | Goldman Sachs | Maintains | Buy → Buy | — | $8.60 | $8.61 | +0.1% | -4.8% | -14.0% | -2.0% | -0.7% | -0.4% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.40 | $7.58 | -9.8% | +2.4% | -4.8% | -14.0% | -2.0% | -0.7% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.91 | $7.91 | +0.0% | +2.4% | +0.0% | +5.6% | +0.9% | -5.1% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.43 | $5.27 | -2.9% | -1.1% | +14.7% | -0.5% | +3.4% | +1.7% |
| May 9 | Wedbush | Maintains | Outperform → Outperform | — | $5.43 | $5.27 | -2.9% | -1.1% | +14.7% | -0.5% | +3.4% | +1.7% |
| Apr 25 | Wedbush | Maintains | Outperform → Outperform | — | $6.19 | $6.08 | -1.8% | -5.0% | +13.1% | -4.4% | +2.5% | +4.4% |
| Apr 25 | BMO Capital | Maintains | Outperform → Outperform | — | $6.19 | $6.08 | -1.8% | -5.0% | +13.1% | -4.4% | +2.5% | +4.4% |
| Mar 28 | BofA Securities | Maintains | Buy → Buy | — | $4.79 | $4.84 | +1.0% | +19.2% | -0.7% | +6.0% | +3.2% | -5.2% |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $5.26 | $5.35 | +1.7% | +0.8% | -1.7% | +0.0% | -5.8% | +0.1% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.26 | $5.35 | +1.7% | +0.8% | -1.7% | +0.0% | -5.8% | +0.1% |
| Jan 5 | BMO Capital | Maintains | Outperform → Outperform | — | $6.53 | $7.00 | +7.2% | -1.2% | +0.3% | -3.1% | +6.9% | +3.9% |
| Nov 21 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.49 | $8.43 | -0.7% | -8.8% | -1.6% | -2.6% | +0.3% | -3.1% |
| Aug 24 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $11.00 | $11.01 | +0.1% | +5.3% | +0.2% | -1.6% | -2.0% | -4.9% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.49 | $17.00 | +3.1% | +3.1% | -0.4% | +6.3% | -6.9% | -2.5% |
| May 24 | Goldman Sachs | Maintains | Buy → Buy | — | $11.84 | $11.43 | -3.5% | +0.3% | +0.6% | +1.3% | +7.9% | -1.1% |
| May 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.52 | $13.40 | -0.9% | -12.4% | +0.3% | +0.6% | +1.3% | +7.9% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.45 | $9.46 | -17.4% | +18.1% | -12.4% | +0.3% | +0.6% | +1.3% |
| Dec 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $17.71 | $17.40 | -1.8% | -0.7% | +2.0% | +6.5% | +1.8% | +3.5% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.68 | $13.94 | +1.9% | -11.5% | +2.9% | +14.1% | -4.2% | -9.0% |
| Mar 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.87 | $16.08 | -4.7% | -7.2% | -17.0% | +2.8% | -0.6% | -2.1% |
| Nov 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.05 | $16.11 | +0.4% | +5.9% | +3.3% | -0.7% | -2.9% | -1.3% |
| Nov 17 | Wedbush | Maintains | Outperform → Outperform | — | $16.05 | $16.11 | +0.4% | +5.9% | +3.3% | -0.7% | -2.9% | -1.3% |
| Nov 17 | Goldman Sachs | Maintains | Buy → Buy | — | $16.05 | $16.11 | +0.4% | +5.9% | +3.3% | -0.7% | -2.9% | -1.3% |
| Nov 17 | Cowen & Co. | Maintains | Outperform → Outperform | — | $16.05 | $16.11 | +0.4% | +5.9% | +3.3% | -0.7% | -2.9% | -1.3% |
No insider trades available.
8-K · 2.02
!! High
Foghorn Therapeutics Inc. -- 8-K 2.02: Earnings Results
Foghorn Therapeutics reported earnings results, with details available in the attached press release, signaling company performance updates relevant to investor evaluation of FHTX's operational and financial trajectory.
May 7
8-K · 8.01
!! High
Foghorn Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Foghorn Therapeutics released a press announcement regarding material developments, though specific details require reviewing the attached exhibit, as forward-looking statements carry inherent risks and uncertainties affecting future outcomes.
Apr 21
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I cannot provide a meaningful analysis because the filing summary lacks critical details about which executive changed roles, their compensation, responsibilities, or whether the change signals strategic shifts or instability.
Mar 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Foghorn Therapeutics disclosed material information via press release and investor presentation on March 11, 2026, which investors should review for potential updates on clinical progress, partnerships, or financial developments affecting stock valuation.
Mar 11
8-K · 5.02
!!! Very High
Foghorn Therapeutics Inc. -- 8-K 5.02: Executive Change
Foghorn Therapeutics appointed Ryan D. Maynard as Chief Financial Officer, signaling potential leadership stability changes that investors should monitor for strategic and financial direction shifts.
Feb 23
Data updated apr 25, 2026 9:04am
· Source: massive.com